Sepah Yasir J
In this database
2
2022
DB Citations
34
across indexed articles
h-index
—
Not available
Total Citations
—
Not available
2 articles in Glaucoma Journal Club
Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.
Use of rhNGF is safe and tolerable in a topical 180-μg/mL formulation.
American journal of ophthalmology2022 Feb33 citations
optic-nerveneuroprotection
Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.
American journal of ophthalmology2022 Oct1 citations